OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Ovid Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.17+0.02 (+0.93%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.69 (+46.62%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Ovid Therapeutics Inc. saw revenue fall 76.2% to $1.58M over the twelve months to Jun 30, 2026. Free cash flow was -$38.33M.
Revenue
$1.58M
-76.2% vs. a year earlier
Operating income
-$58.36M
TTM Q2 2026
Free cash flow
-$38.33M
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.58M
- Net income
- -$34.49M
- Free cash flow
- -$38.33M
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
$1.58M-76.2% YoY
Operating income
-$58.36M
Net income
-$34.49M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months